The MedTech company NeoDynamics showcased its novel biopsy system NeoNavia at the 41st Congress of the German Society of Senology, the most important breast cancer congress in the German speaking area when it resumed after a break during the pandemic. Professor Marc Thill presented an update on the PULSE study, involving NeoNavia at the meeting. Apart from Professor Marc Thill’s presentation, NeoNavia was also referred to as a new method for axillary management by PD Dr Ines Gruber from the University Hospital Tübingen. NeoDynamics also participated in the conference, that ended this weekend, with a sales booth.
“It is great that the most important breast cancer congress in Germany is back as a live event. We could showcase NeoNavia hands-on at our booth and pick up new German and Swiss leads that we will follow up on. We strengthened relationships with key opinion leaders and are especially excited that NeoNavia found its way into several presentations at the educational sessions. We’re gaining traction,” says Renate Reiss, country manager for the DACH region.
Neodynamics is a Swedish medical technology company that works to improve the treatment and diagnosis of cancer. The company’s first product is NeoNavia, which is a modern biopsy system with a completely new and patented pulse technology that is intended to be used for ultrasound-guided tissue sampling. The NeoNavia pulse biopsy system is designed to offer physicians and patients accurate and reliable tissue sampling that enables accurate diagnosis and individualized treatment. NeoNavia is being evaluated for the diagnosis of breast cancer at leading clinics in the UK, Germany and Sweden.
Disclaimer: HC Andersen Capital receives payment from NeoDynamics for a DigitalIR/Corporate Visibility agreement.